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Abstract
In just 10 years from its discovery in 2000, interleukin-23 has quickly moved from being recognized as
a pro-inflammatory cytokine to a key player and potential therapeutic target in psoriasis.
Introduction and context
Interleukin-23 (IL-23) is a heterodimeric cytokine, consis-
ting of a unique IL-23p19 subunit paired with a common
IL-12/23p40 subunit, which is shared with IL-12 [1]. It is
mainly produced by activated myeloid cells, as well as
epithelial and endothelial cells, and signals through its
heterodimeric IL-23 receptor complex, consisting of a
unique IL-23 receptor (IL-23R) subunit paired with a
common IL-12Rb1 subunit shared with the IL-12 receptor
complex (Figure 1) [2]. Shortly after its discovery, IL-23
emerged as a key pro-inflammatory cytokine driving
autoimmunity, in both animal models and human
diseases. In mice, lack of IL-23 was found to make them
resistanttoanimalmodelsofarthritisandmultiplesclerosis
[3,4]. In addition, models of experimental colitis pointed
towards a role for IL-23 as a key tissue-specific effector
cytokine that amplifies the inflammatory response [5,6]. In
humans, IL-23 was found to be over-expressed in clinical
samples of several immune-mediated diseases, including
Crohn’s disease, rheumatoid arthritis and multiple sclero-
sis. At the same time, IL-23 was strongly implicated in the
developmentof anovel,IL-17A-producing Thelper(Th)17
cellsubset,whichhadjustbeendiscoveredandidentifiedas
a main player in autoimmunity [7].
These findings have set the scene for a major re-
evaluation of the immunopathogenesis of psoriasis.
Psoriasis is a T-cell-mediated, chronic inflammatory
skin disease that results from a complex interplay
between environmental and genetic factors [8]. Psoriasis
had been traditionally regarded as a Th1-type and tumor
necrosis factor (TNF)-driven disease but this perception
was challenged after the discovery of IL-23 and experi-
mental and clinical data that put the spotlight on the
IL-23/Th17 axis in psoriasis.
Intradermal injection of IL-23 or over-expression of
IL-12/23p40 in mouse keratinocytes (KCs) was shown to
lead to erythema, induration and prominent dermal
papillary blood vessels with histopathological features
resembling psoriasis [9,10]. IL-23 was found to be highly
expressed in psoriatic skin lesions, where it is mainly
produced by tissue-resident and/or recruited dendritic
cells (DCs) with some possible contribution by KCs
[11,12]. Moreover, the clinical benefit from conventional
and biologic systemic therapies targeting psoriasis was
found to correlate with IL-23 down-regulation in
psoriatic patients [13,14], and a proof-of-concept phase
I study testing efficacy and safety of ustekinumab, a
human monoclonal antibody directed against IL12/
23p40, showed promising results in the treatment of
moderate to severe psoriasis [15]. Consistently, IL-17A
was shown to be expressed in psoriatic skin [9],
suggesting that Th17 cells could possibly infiltrate
psoriatic lesions, contributing to chronic inflammation.
Major recent advances
In the past 3 years major advances in our understanding
of psoriasis pathogenesis have arisen from exciting
genetic, immunological and clinical findings, all unam-
biguously converging on the pivotal role of the IL-23/
Th17 axis in psoriasis [16] .
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edly shown that several genes of the IL-23 pathway are
associated with psoriasis. We and others have found that
single nucleotide polymorphisms in both the IL12B and
IL23R genes, coding for IL-12/23p40 and IL23R subunits,
respectively, are associated with psoriasis [17,18]. Of
interest, the non-synonymous nucleotide substitution in
the IL23R gene, resulting in an arginine to glutamine
exchange (Arg381Gln) in the cytoplasmic domain of the
receptor, has a protective role not only in psoriasis, but
also in other immune-mediated diseases, including
Crohn’s disease [19], suggesting that genetic variants in
the IL23R gene might be common determinants of
autoimmunity.Finally,ageneticassociationwithpsoriasis
hasrecentlybeenfoundalsoforvariantsintheIL23Agene,
which codes for the IL-23p19 subunit [20].
Human Th17 cells have been thoroughly characterized
with respect to their cytokine requirements (transform-
ing growth factor-beta plus one of several pro-inflam-
matory cytokines, i.e., IL-6, IL-1b, IL-23 and IL-21),
lineage markers (master regulator transcription factor
RORgt and surface markers CCR6 and IL-23R) and
cytokine production (IL-17A, but also IL-17F, IFN-g, IL-
22 and IL-26) [21,22]. Likewise, the role of IL-23 with
regard to Th17 cell biology has been clarified and
refined. Although not required for early Th17 develop-
ment, IL-23 plays a role in terminal differentiation of
effector Th17 cells and their pathogenicity in peripheral
tissues [23]. These findings are of relevance to psoriasis
as Th17 cells have been identified in psoriatic skin [24]
and Th17 cytokines have been found to be expressed at
high levels in lesional skin and to induce the production
of antimicrobial peptides and chemokines by KCs [21].
Of particular interest is the link between IL-23 and IL-22
production by Th17 cells. IL-23 injection in mice induces
IL-22-dependent dermal inflammation, KC hyperproli-
feration and epidermal acanthosis [25], while IL-22
neutralization is able to prevent the development of
psoriasiform skin lesions [26]. Moreover, CCR6 also
seems to be required for IL-23-induced and IL-22-
mediated psoriasis-like skin inflammation in mice [27],
and it has been shown that Th17 cytokines can stimulate
the production of the CCR6 ligand CCL20 by KCs,
suggesting a possible mechanism by which Th17 cells
maintain their continual presence in psoriatic skin [28].
Therefore, in the ‘IL-23/Th17 axis’ model of psoriasis,
IL-23 secreted by dermal DCs is able to induce Th17 cell
activation and the release of pro-inflammatory Th17
cytokines that acts on KCs, which, in turn, sustain and
amplify the chronic inflammatory disease process by
producing more IL-23 as well as pro-inflammatory
cytokines, chemokines, members of the S100 family
and antimicrobial peptides (e.g., TNF, IL-8, CCL-20,
S100 molecules, defensins and cathelicidins; Figure 2).
The anti-IL-12/IL-23 monoclonal antibody ustekinumab
has been approved in Canada (December 2008), Europe
(January 2009) and USA (September 2009) for human
use in moderate to severe psoriasis. Designed in the late
1990s with the aim of blocking IL-12 (IL-23 was still
unknown at that time), ustekinumab targets the com-
mon IL-12/23p40 subunit, thus blocking both IL-12 and
IL-23 signalling. Phase 3 clinical trials (Phoenix 1 and
Phoenix 2) involving more than 2000 patients have
shown that up to 76% of patients achieve at least a 75%
improvement in the Psoriasis Area and Severity Index
(PASI 75) at week 24, with only mild and non-serious
adverse events [29,30]. Very recently, ustekinumab has
shown higher efficacy than the anti-TNF drug etanercept,
with 71% of patients in the high-dose ustekinumab
group achieving PASI 75 compared to 49% in the
etanercept group after 12 weeks. Interestingly, up to
49% of the non-responders in the etanercept group had
a PASI 75 response when crossed over to high-dose
ustekinumab [31].
Future directions
IL-23 represents one of the rare instances in which basic
science has rapidly progressed to preclinical studies and
resulted in a clinical intervention that supports the
Figure 1. Interleukin-23 and its receptor complex
IL-12Rβ1 IL-23R
IL-23p19 IL-12p40
IL-23 receptor complex
IL-23
Interleukin (IL)-23 is a heterodimeric cytokine composed of IL-12/23p40
and IL-23p19 subunits. It binds to the IL-23 receptor complex composed of
IL-12Rb1 and IL-23R subunits.
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psoriasis. However, several questions remain to be
answered. First, what is the functional role of the IL-23
pathway gene variants associated with psoriasis? Second,
is there any correlation between these genetic variants
and disease phenotype? Third, are the newly discovered
genetic variants of any use in pharmacogenetic studies to
predict treatment response?
Moreover, a recently described Th cell subset, IL-22-
producing Th22 cells, has been identified in psoriasis
[32]. It will be interesting to investigate if IL-23 plays a
role in Th22 activation in psoriasis. Finally, the ultimate
question is whether inhibition of IL-23 on its own, with
either monoclonal antibodies or small molecules, is
effective. Clinical studies to test the safety and effective-
ness of a monoclonal anti IL-23 are currently under way
Figure 2. The interleukin (IL)-23/Th17 axis in the immunopathogenesis of psoriasis
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In the ‘IL-23/Th17 axis’ model of psoriasis, T helper 17 (Th17) cells interact with skin-resident cells, contributing to the psoriatic disease phenotype,
characterized by scaly plaques and thickened epidermis (acanthosis), with elongated rete ridges and hyperproliferative keratinocytes (KCs) retaining the
nucleus in the stratum corneum (parakeratosis), as well as dermal inflammatory cell infiltrate. IL-23 secreted by dermal dendritic cells (DCs) is able to induce
Th17 cell activation with production of pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22 and IFN-g. These cytokines act on KCs, inducing epidermal
hyperplasia and KC activation. Activated KCs produce pro-inflammatory mediators, including chemokines, members of the S100 family, pro-inflammatory
cytokines and antimicrobial peptides. In particular, CCL20 is able to recruit more CCR6+ Th17 cells. Moreover, KCs might produce IL-23, which could
mediate crosstalk with Th17 cells in synergy with IL-23 produced by dermal DCs, thus further sustaining and amplifying skin inflammation.
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of IL-23 in the immunopathogenesis of psoriasis.
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